Perpetual Ltd Purchases 24,355 Shares of Boston Scientific Corporation $BSX

Key Points

• Perpetual Ltd increased its Boston Scientific position by 182.5% in the third quarter, purchasing 24,355 additional shares for a total holding of 37,699 shares valued at approximately $1.65 million. Institutional investors collectively own 89.07% of the company.
• Analysts remain broadly positive, with Boston Scientific receiving a “Moderate Buy” consensus rating and an average price target of $68.43, although several firms recently lowered their targets. Company insiders also purchased roughly $9.4 million in shares during the latest quarter.
• Boston Scientific reported quarterly EPS of $0.86, exceeding estimates of $0.83, while revenue rose 7.5% year over year to $5.44 billion. Shares opened at $43.33, near the company’s 52-week low of $41.38.

Perpetual Ltd increased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 182.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 37,699 shares of the medical equipment provider's stock after buying an additional 24,355 shares during the period. Perpetual Ltd's holdings in Boston Scientific were worth $1,646,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. GK Wealth Management LLC acquired a new position in shares of Boston Scientific during the third quarter valued at about $41,000. Riversedge Advisors LLC boosted its holdings in Boston Scientific by 83.2% during the third quarter. Riversedge Advisors LLC now owns 13,733 shares of the medical equipment provider's stock valued at $599,000 after purchasing an additional 6,237 shares in the last quarter. Wedmont Private Capital grew its stake in shares of Boston Scientific by 6.3% in the 3rd quarter. Wedmont Private Capital now owns 27,800 shares of the medical equipment provider's stock valued at $1,213,000 after purchasing an additional 1,652 shares during the period. LifeGoal Investments LLC bought a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $428,000. Finally, Mn Services Vermogensbeheer B.V. raised its holdings in shares of Boston Scientific by 8.1% in the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 467,972 shares of the medical equipment provider's stock worth $20,427,000 after buying an additional 34,959 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the subject of several analyst reports. Needham & Company LLC cut their target price on Boston Scientific from $77.00 to $57.00 and set a "buy" rating for the company in a research report on Wednesday, July 8th. Wall Street Zen lowered Boston Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 2nd. Oppenheimer cut their price objective on Boston Scientific from $85.00 to $65.00 and set an "outperform" rating for the company in a report on Monday, September 21st. Piper Sandler cut their price objective on Boston Scientific from $65.00 to $60.00 in a report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $60.00 target price (down from $75.00) on shares of Boston Scientific in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of "Moderate Buy" and an average target price of $68.43.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael Mahoney acquired 186,240 shares of the company's stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares of the company's stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David Habiger bought 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 194,522 shares of company stock worth $9,385,210 in the last quarter. Corporate insiders own 0.34% of the company's stock.

Boston Scientific Price Performance

Shares of BSX stock opened at $43.33 on Wednesday. The stock's fifty day moving average is $46.35 and its 200-day moving average is $50.16. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The stock has a market capitalization of $62.79 billion, a PE ratio of 17.54, a PEG ratio of 1.05 and a beta of 0.58. Boston Scientific Corporation has a 52 week low of $41.38 and a 52 week high of $105.65.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business's quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.25 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.